Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 20/20 | 1.00 |
| ▸ | WDR77 | Q9BQA1 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20721439 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL20721437 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL32675123 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL32675142 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29390536 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29391763 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL29684140 | 0.99 | PRMT5 (0.98) | PRMT5WDR77 | |
| Sulfuric Acid SCHEMBL20721567 | 0.96 | PRMT5 (0.92) | PRMT5WDR77 | |
| Sulfuric Acid SCHEMBL20721569 | 0.96 | PRMT5 (0.92) | PRMT5WDR77 | |
| Sulfuric Acid SCHEMBL29652234 | 0.96 | PRMT5 (0.92) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208416-B2 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-12-28 | — | — | US | claimed |
| EP-3665179-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2021-06-09 | — | — | EP | claimed |
| US-20200361946-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-11-19 | — | — | US | claimed |
| US-10570140-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-02-25 | — | — | US | claimed |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-02-14 | — | — | US | claimed |
| US-20220251088-A1 | Processes for Making PRMT5 Inhibitors | PRELUDE THERAPEUTICS, INCORPORATED | 2022-08-11 | — | — | US | disclosed |
| US-20220160713-A1 | SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | WILMINGTON PHARMATECH COMPANY, LLC | 2022-05-26 | — | — | US | disclosed |
| US-20220160713-A1 | SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | WILMINGTON PHARMATECH COMPANY, LLC | 2022-05-26 | — | — | US | disclosed |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10570140-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570140-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885 |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 76/4885 |
| US-11208416-B2 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885 |
| US-20220160713-A1 | SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 153/4885 |
| US-20220251088-A1 | Processes for Making PRMT5 Inhibitors | PRMT5, PRMT6, PRMT8 | PRMT5 1/4885WDR77 255/4885 |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885 |
| US-10570140-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-20200361946-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.